Serious personal injury cases often take months or years to resolve, and the financial pressure of lost wages, mounting medical bills, and ordinary living expenses can force injured plaintiffs into a difficult position: settle a valid claim early for less than it is worth simply to relieve immediate financial strain, or hold out for full value while facing genuine hardship in the meantime. Lawsuit funding, also known as pre-settlement funding or legal funding, has emerged as a tool designed to address exactly this gap, though understanding how it actually works, and what it is not, matters considerably before pursuing it.
What Lawsuit Funding Actually Is
Lawsuit funding is a financial transaction in which a company provides a cash advance to a plaintiff with a pending personal injury claim, in exchange for a portion of the eventual settlement or verdict. Critically, this is not a loan in the traditional legal sense in most states. The funding is structured as a non-recourse debt advance, meaning that if the underlying case is unsuccessful, the plaintiff typically owes nothing back to the funding company.
This non-recourse structure is what distinguishes legal funding from conventional lending and is central to how the product is regulated, or in many states, left largely unregulated. Because the funding company bears the risk of the case’s outcome, the industry has developed underwriting practices that closely resemble how insurance companies or investors evaluate risk rather than how traditional lenders evaluate a borrower’s ability to repay.
The application process typically requires the funding company to review case details directly with the plaintiff’s attorney, since the strength of the underlying legal claim, not the plaintiff’s credit history or income, determines both whether funding will be approved and how much.
How Funding Amounts and Costs Are Determined
Lawsuit funding companies generally advance a fraction of a case’s estimated total value, often in the range of 10 to 20 percent, reflecting both the uncertainty inherent in any pending litigation and the need to preserve enough anticipated settlement value to satisfy the plaintiff’s attorney fees, medical liens, and other claims against the proceeds.
The cost structure varies significantly between funding companies, and this variation matters enormously for plaintiffs evaluating whether to pursue funding at all. Some companies charge simple monthly fees on the advanced amount, while others apply compounding structures that can substantially increase the total repayment obligation the longer a case remains pending. According to the Consumer Financial Protection Bureau, litigation funding products have drawn increasing regulatory attention in recent years precisely because the range of pricing structures across the industry can make it difficult for consumers to compare offers and understand the true cost of funding before committing.
High Rise Financial’s personal injury lawsuit funding product reflects the industry’s broader move toward more transparent fee structures, an evolution that has become increasingly important as both plaintiffs’ attorneys and consumer advocates have pushed for greater clarity in an industry that has historically varied widely in its disclosure practices.
When Lawsuit Funding Makes Sense, and When It Does Not
Lawsuit funding is generally most appropriate for plaintiffs facing genuine financial hardship during litigation, particularly when medical bills are accumulating, lost wages have created a real gap in household income, and the underlying case has strong liability facts that make a favorable outcome reasonably likely.
It is generally less appropriate as a routine financial planning tool, or for cases where liability is genuinely uncertain, since the cost of funding compounds over time and can meaningfully reduce a plaintiff’s ultimate net recovery if a case takes longer than expected to resolve. Attorneys generally advise clients to treat legal funding as a tool for addressing genuine emergency financial need rather than a way to access anticipated settlement proceeds earlier simply for convenience.
The relationship between funding and attorney fee arrangements also deserves careful attention. Because most personal injury cases are handled on a contingency basis, plaintiffs need to understand how a funding advance interacts with the attorney’s fee, any medical liens against the settlement, and the plaintiff’s own net recovery, ideally before signing any funding agreement rather than after.
Questions Plaintiffs Should Ask Before Accepting Funding
Several questions help plaintiffs evaluate whether a specific funding offer, and the funding option generally, makes sense for their situation.
Understanding the total repayment obligation at various points in time, not just at signing but at three months, six months, and a year into the case, helps plaintiffs anticipate how the cost of funding will affect their net recovery if litigation takes longer than initially expected. Reputable funding companies should be willing to provide this kind of amortization information clearly and in writing.
Confirming that the funding is genuinely non-recourse, meaning nothing is owed if the case is lost, protects against the rare but real risk of funding products that are structured more like traditional loans despite being marketed as advances.
Discussing any funding decision directly with the attorney handling the underlying case is essential, since the attorney has visibility into case strategy, anticipated timeline, and settlement value that the plaintiff alone may not have, and most attorneys have direct experience working with funding companies and can help evaluate whether a specific offer is reasonable relative to industry norms.
Lawsuit funding fills a genuine need for plaintiffs facing financial hardship during protracted litigation, but it is a financial product that requires the same careful evaluation as any other significant financial decision, ideally undertaken in close consultation with legal counsel who understands both the underlying case and the funding product being considered.